NIKKEI 225
29,683.09 +84.43 (+0.29%) HANG SENG
25,319.72 -330.36 (-1.29%) GOLD FUTURES
1,861.20 -0.20 (-0.01%) DOW
35,870.95 -60.10 (-0.17%) BTC-GBP
43,078.96 -511.61 (-1.17%) CMC Crypto 200
1,402.14 -65.80 (-4.48%)
CureVac N.V. (CVAC)
- Motley Fool
CureVac (CVAC) Q3 2021 Earnings Call Transcript
On the call with me from CureVac are Franz-Werner Haas, the chief executive officer of CureVac; Klaus Edvardsen, our chief development officer; and Pierre Kemula, chief financial officer of CureVac. Mariola Fotin-Mleczek, our chief technology officer, will be available for the Q&A session.
- EQS Group
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
DGAP-News: CureVac / Key word(s): Quarter Results18.11.2021 / 22:10 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update - Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review- Nature publication of promising pre-clinical results for second-ge
- EQS Group
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
DGAP-News: CureVac / Key word(s): Scientific publication18.11.2021 / 11:42 The issuer is solely responsible for the content of this announcement.CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA VaccineTÜBINGEN, Germany/ BOSTON, USA - November 18, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucle
